drugset / Trial / NCT07145450
Master Protocol of TCR-modified T Cell Therapy Targeting HLA-restricted KRAS Antigen Administered in Adult Patients With Metastatic or Locally Advanced PDAC
Non-randomizedParallel-groupOpen-labelTreatment
Summary
This is an open-label, multi-centre, single-arm Phase 1/2 clinical trial of the safety, expansion, persistence and clinical activity of a set of engineered autologous T cells products each capable of recognizing a specific combination mutated KRAS and HLA, activating the T cells and exerting anti- tumour activity in patients with metastatic or locally advanced PDAC.
Timeline
- Start
- 2025-07-03
- Primary completion
- 2030-04-02
- Completion
- 2030-07-31
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | ANOC-001 | Cell therapy | — | Intravenous |
| Subject | ANOC-002 | Cell therapy | — | Intravenous |
| Subject | ANOC-003 | Cell therapy | — | Intravenous |
| Background | Cyclophosphamide | Other / unclassified | — | — |
| Background | Fludarabine | Small molecule | — | — |